Last edition
News about "ADHD treatment"
Otsuka Receives US FDA Approval for First-in-Class SIMTRIYO
The US Food and Drug Administration (FDA) has approved Otsuka's SIMTRIYO, the first Norepinephrine, Dopamine, Serotonin Reuptake Inhibitor (NDSRI) for treating ADHD in adults and children aged 6 years and older weighing at least 20 kg.
ADHD Treatment | 27/07/2026 | By News Bureau
Granules Pharma Gets US FDA Tentative Approval for Generic ADZENYS XR-ODT
Granules Pharmaceuticals Inc has received tentative approval from the US FDA for its generic version of Amphetamine Extended-Release Orally Disintegrating Tablets (ADZENYS XR-ODT), which will be manufactured at the company’s US-based facility in Chantilly, Virginia.
ADHD Treatment | 22/12/2025 | By News Bureau | 217
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy